Kim D, et al. - The researchers compared the cost-effectiveness of secukinumab vs adalimumab at 1 and 2 years of treatment in patients with ankylosing spondylitis (AS) through analysis of the cost per responder reported in randomized controlled trials from the Korean perspective. In secukinumab, 40% lower cost per AS International Working Group (ASAS) 20 and ASAS 40 responder was noted in comparison to adalimumab. Secukinumab exhibited lower costs per responder by 25% as that of the adalimumab with a loading dosage of secukinumab at 52 and 104 weeks. Hence, the costs per responder in association with ASAS 20 and 40 response rates were consistently less for secukinumab compared with adalimumab. Also, for patients with AS, treatment with secukinumab might be a cost-saving treatment option in South Korea.